Asset: Novel PDE3A-targeting dual-protein molecular glue degrader
Development Stage: PCC
Indication: Gastrointestinal stromal tumor (GIST) and multiple solid tumors
Key Asset Highlights:
- Adopts a novel first-in-class molecular glue mechanism, specifically inducing stable ternary complex formation to trigger targeted tumor cell apoptosis, breaking conventional targeted drug design logic.
- Delivers potent and selective anti-tumor activity against double-positive tumors, exhibiting prominent efficacy in TKI-resistant gastrointestinal stromal tumor models with unmet clinical treatment needs.
- Demonstrates broad anti-tumor spectrum across multiple solid tumor subtypes beyond GIST, showing robust in vivo tumor growth inhibition efficacy in diversified preclinical solid tumor models.
- Possesses unique differentiated advantages over traditional kinase inhibitors, effectively overcoming drug resistance caused by target mutation and pathway compensation, providing a novel therapeutic strategy for refractory solid tumors.
- Displays favorable druggability with optimized physicochemical properties and oral pharmacokinetic profiles, supporting flexible administration and long-term clinical treatment application.
- Backed by a systematic intellectual property layout covering core structure and mechanism, securing exclusive global development and commercialization potential for novel molecular glue anti-tumor therapy.
If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
